Skip to Content
Merck
  • TRIM35 negatively regulates TLR7- and TLR9-mediated type I interferon production by targeting IRF7.

TRIM35 negatively regulates TLR7- and TLR9-mediated type I interferon production by targeting IRF7.

FEBS letters (2015-04-25)
Yanming Wang, Shanshan Yan, Bo Yang, Yan Wang, Haiyan Zhou, Qiaoshi Lian, Bing Sun
ABSTRACT

Toll-like receptor 7 (TLR7) and TLR9 sense viral nucleic acids and induce type I IFN production, which must be properly controlled to avoid autoimmune diseases. Here, we report the negative regulation of TLR7/9-mediated type I IFN production by TRIM35. TRIM35 expression is induced by TLR7/9 stimulation and then interacts with IRF7, which is the master regulator of type I IFN response. Furthermore, TRIM35 promotes the K48-linked ubiquitination of IRF7 and induces its degradation via a proteasome-dependent pathway. Therefore, TRIM35 is a negative feedback regulator of TLR7/9-mediated type I IFN production due to its ability to suppress the stability of IRF7.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-TRIM35 antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-Actin antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Monoclonal ANTI-FLAG® M2 antibody produced in mouse, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)